05 December 2018 3 Min Read
Takeda investors back $59bn Shire deal, but wary of debt load
Takeda will be joining the ranks of the world’s top 10 drugmakers and gaining expertise in rare diseases through the deal
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In